DVL1 and breast carcinoma: Taken together, these data demonstrate that, in human breast cancer cells, Wnt1 activates the ERK1/2 pathway in a WNT ligand- and DVL-dependent manner and this is independent of canonical signaling via β-catenin stabilization.